• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

ACC 2014

ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 By Arezu Sarvestani Leave a Comment

fired/hired

The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

Filed Under: News Well, Replacement Heart Valves Tagged With: ACC 2014, American College of Cardiology Conference (ACC), Boston Scientific, Clinical Trials, Conference coverage, Edwards Lifesciences, Hypertension, Renal

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

March 31, 2014 By Brad Perriello Leave a Comment

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.

Filed Under: News Well, Replacement Heart Valves Tagged With: Abbott, ACC 2014, American College of Cardiology, Bariatrics, Boston Scientific, Clinical Trials, Stent Wars

ACC 2014 UPDATE: Reaction to Medtronic’s Symplicity renal denervation data

March 31, 2014 By Brad Perriello Leave a Comment

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

Filed Under: News Well Tagged With: ACC 2014, American College of Cardiology, Boston Scientific, Clinical Trials, Hypertension, Minnesota, stjudemedical

ACC 2014: Sapien XT bests CoreValve in small head-to-head study

March 31, 2014 By Brad Perriello Leave a Comment

ACC 2014: Sapien XT bests CoreValve in small head-to-head study

UPDATED March 31, 2014, with comment from Medtronic

Filed Under: News Well, Replacement Heart Valves, Wall Street Beat Tagged With: ACC 2014, American College of Cardiology, Edwards Lifesciences, Minnesota

ACC 2014: Medtronic details Symplicity renal denervation data

March 29, 2014 By Ingrid Mezo Leave a Comment

YYmeta

Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

Filed Under: News Well Tagged With: ACC 2014, American College of Cardiology, Clinical Trials, Hypertension, Minnesota, Renal

ACC 2014: Medtronic can skip FDA panel on positive high-risk CoreValve data

March 29, 2014 By Brad Perriello Leave a Comment

ACC 2014: Medtronic can skip FDA panel on positive high-risk CoreValve data

Medtronic (NYSE:MDT) said today that the FDA will allow it to skip an advisory panel on high-risk patients for its CoreValve replacement heart valve, after data from a clinical study showed the transcatheter aortic heart implant is superior to open heart surgery.

Filed Under: Food & Drug Administration (FDA), News Well, Replacement Heart Valves Tagged With: ACC 2014, Clinical Trials, Minnesota

Medtech gears up for Medtronic’s RDN trial results | MassDevice.com On Call

March 28, 2014 By Brad Perriello Leave a Comment

MassDevice.com On Call

MASSDEVICE ON CALL — The medical device world will be watching intently this weekend as Medtronic (NYSE:MDT) releases data for the 1st time from a failed clinical trial of its Symplicity renal denervation device.

Filed Under: News Well Tagged With: ACC 2014, American College of Cardiology, Clinical Trials, Hypertension, Minnesota

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS